EBV-associated lymphoproliferative disorder of CNS associated with the use of mycophenolate mofetil

Brian Patrick O'Neill, Steven Vernino, Ahmet Dogan, Caterina Giannini

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Epstein-Barr virus (EBV)-associated lymphoid proliferations are a well-recognized complication of congenital or acquired systemic immunosuppression. The CNS is a frequent site for development of such lymphoid proliferations. We describe the clinical, imaging, and pathologic observations of a CNS disorder histologically similar to posttransplantation lymphoproliferative disorder that occurred in four patients with autoimmune disease treated with mycophenolate mofetil (MM). Two patients had polymorphous lymphoplasmacytic infiltration of brain parenchyma, and two had monomorphous infiltrations consistent with diffuse large B-cell lymphoma. In situ hybridization for EBV-encoded RNA was positive in all four patients. All patients improved after MM withdrawal and the use of rituximab. Because of a favorable toxicity profile, MM is now being used as steroid-sparing immunomodulatory therapy in autoimmune disorders. Based on our experience presented herein, we recommend caution in patient selection for MM and strict surveillance of those patients with autoimmune disorders who receive MM.

Original languageEnglish (US)
Pages (from-to)364-369
Number of pages6
JournalNeuro-Oncology
Volume9
Issue number3
DOIs
StatePublished - Jul 2007

Fingerprint

Mycophenolic Acid
Lymphoproliferative Disorders
Human Herpesvirus 4
Immunomodulation
Lymphoma, Large B-Cell, Diffuse
Immunosuppression
Patient Selection
Autoimmune Diseases
In Situ Hybridization
Steroids
RNA
Brain

Keywords

  • CNS
  • EBV
  • Lymphoproliferation
  • Mycophenolate
  • Primary CNS lymphoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Clinical Neurology

Cite this

EBV-associated lymphoproliferative disorder of CNS associated with the use of mycophenolate mofetil. / O'Neill, Brian Patrick; Vernino, Steven; Dogan, Ahmet; Giannini, Caterina.

In: Neuro-Oncology, Vol. 9, No. 3, 07.2007, p. 364-369.

Research output: Contribution to journalArticle

O'Neill, Brian Patrick ; Vernino, Steven ; Dogan, Ahmet ; Giannini, Caterina. / EBV-associated lymphoproliferative disorder of CNS associated with the use of mycophenolate mofetil. In: Neuro-Oncology. 2007 ; Vol. 9, No. 3. pp. 364-369.
@article{b1ed6337890a42cc9f91e4590bec42ac,
title = "EBV-associated lymphoproliferative disorder of CNS associated with the use of mycophenolate mofetil",
abstract = "Epstein-Barr virus (EBV)-associated lymphoid proliferations are a well-recognized complication of congenital or acquired systemic immunosuppression. The CNS is a frequent site for development of such lymphoid proliferations. We describe the clinical, imaging, and pathologic observations of a CNS disorder histologically similar to posttransplantation lymphoproliferative disorder that occurred in four patients with autoimmune disease treated with mycophenolate mofetil (MM). Two patients had polymorphous lymphoplasmacytic infiltration of brain parenchyma, and two had monomorphous infiltrations consistent with diffuse large B-cell lymphoma. In situ hybridization for EBV-encoded RNA was positive in all four patients. All patients improved after MM withdrawal and the use of rituximab. Because of a favorable toxicity profile, MM is now being used as steroid-sparing immunomodulatory therapy in autoimmune disorders. Based on our experience presented herein, we recommend caution in patient selection for MM and strict surveillance of those patients with autoimmune disorders who receive MM.",
keywords = "CNS, EBV, Lymphoproliferation, Mycophenolate, Primary CNS lymphoma",
author = "O'Neill, {Brian Patrick} and Steven Vernino and Ahmet Dogan and Caterina Giannini",
year = "2007",
month = "7",
doi = "10.1215/15228517-2007-004",
language = "English (US)",
volume = "9",
pages = "364--369",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - EBV-associated lymphoproliferative disorder of CNS associated with the use of mycophenolate mofetil

AU - O'Neill, Brian Patrick

AU - Vernino, Steven

AU - Dogan, Ahmet

AU - Giannini, Caterina

PY - 2007/7

Y1 - 2007/7

N2 - Epstein-Barr virus (EBV)-associated lymphoid proliferations are a well-recognized complication of congenital or acquired systemic immunosuppression. The CNS is a frequent site for development of such lymphoid proliferations. We describe the clinical, imaging, and pathologic observations of a CNS disorder histologically similar to posttransplantation lymphoproliferative disorder that occurred in four patients with autoimmune disease treated with mycophenolate mofetil (MM). Two patients had polymorphous lymphoplasmacytic infiltration of brain parenchyma, and two had monomorphous infiltrations consistent with diffuse large B-cell lymphoma. In situ hybridization for EBV-encoded RNA was positive in all four patients. All patients improved after MM withdrawal and the use of rituximab. Because of a favorable toxicity profile, MM is now being used as steroid-sparing immunomodulatory therapy in autoimmune disorders. Based on our experience presented herein, we recommend caution in patient selection for MM and strict surveillance of those patients with autoimmune disorders who receive MM.

AB - Epstein-Barr virus (EBV)-associated lymphoid proliferations are a well-recognized complication of congenital or acquired systemic immunosuppression. The CNS is a frequent site for development of such lymphoid proliferations. We describe the clinical, imaging, and pathologic observations of a CNS disorder histologically similar to posttransplantation lymphoproliferative disorder that occurred in four patients with autoimmune disease treated with mycophenolate mofetil (MM). Two patients had polymorphous lymphoplasmacytic infiltration of brain parenchyma, and two had monomorphous infiltrations consistent with diffuse large B-cell lymphoma. In situ hybridization for EBV-encoded RNA was positive in all four patients. All patients improved after MM withdrawal and the use of rituximab. Because of a favorable toxicity profile, MM is now being used as steroid-sparing immunomodulatory therapy in autoimmune disorders. Based on our experience presented herein, we recommend caution in patient selection for MM and strict surveillance of those patients with autoimmune disorders who receive MM.

KW - CNS

KW - EBV

KW - Lymphoproliferation

KW - Mycophenolate

KW - Primary CNS lymphoma

UR - http://www.scopus.com/inward/record.url?scp=34547416731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547416731&partnerID=8YFLogxK

U2 - 10.1215/15228517-2007-004

DO - 10.1215/15228517-2007-004

M3 - Article

VL - 9

SP - 364

EP - 369

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 3

ER -